Immunic, inc. to participate in investor and scientific conferences in march

New york, march 8, 2022 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in march: march 13-15: 34th annual roth conference. duane nash, m.d.
IMUX Ratings Summary
IMUX Quant Ranking